The Medipattern Corporation
TSX VENTURE : MKI

The Medipattern Corporation

May 24, 2006 07:28 ET

Medipattern and Confirma Inc. Announce Strategic Partnership to Deliver B-CAD MRI'TM' to CADstream'TM' Customers

TORONTO, ONTARIO--(CCNMatthews - May 24, 2006) -

Attention: Business/Financial Editors:

The Medipattern Corporation (TSX VENTURE:MKI), an award-winning innovator in computer-aided diagnosis (CAD) for medical imaging, today announced a strategic partnership with the leading provider of Magnetic Resonance Imaging (MRI) CAD, Confirma, Inc., to add Medipattern's advanced morphology analysis feature, B-CAD MRI™, to Confirma's MRI product, CADstream. has the largest installed base of MRI CAD systems, with more than 450 installations of CADstream through established partnerships with such companies as GE Healthcare, Hologic, iCAD, and Vital Images. Confirma has partnered with more than 200 imaging centers and corporate partners worldwide since 2003, helping develop standardized, high-performance breast MRI programs that deliver premium patient care.

Medipattern's B-CAD MRI, which will be integrated into Confirma's CADstream, is designed to analyze clinical characteristics, such as a lesion's size and margin, and produces a detailed electronic report to assist radiologists in classifying breast lesion morphology. CADstream automates analysis and reporting of breast MRI studies, incorporating the ACR BI-RADS® Atlas, and has the largest installed base of all CAD systems for MRI.

"Morphology analysis is a valuable element in comprehensive, high-quality breast MRI interpretation," said Wayne Wager, President and CEO of Confirma, Inc. "With the addition of Medipattern's B-CAD MRI to our CADstream, radiologists now have a more comprehensive analysis package to aid in improved breast MRI interpretation. Together, Medipattern and Confirma will offer the most advanced CAD system for breast MRI available on the market."

"We are pleased to partner with Confirma, the market leader in MRI CAD systems, to deliver advanced morphology analysis tools to CADstream customers," said Jeff Collins, CEO of Medipattern. "Breast MRI has become an integral tool for earlier breast cancer detection. In conjunction with CAD, which has gained widespread acceptance, MRI is now both more accessible and more comprehensible, thereby benefiting both practitioners and patients. B-CAD MRI's addition to CADstream offers radiologists the prospect of improvements in diagnostic confidence in breast MRI."

B-CAD MRI, one of Medipattern's CADENZA™ family of CAD products, uses pattern recognition algorithms to assist radiologists in their efforts to classify and characterize breast lesions. The software helps practitioners to recognize and identify the morphological features defined by the American College of Radiology (ACR) BI-RADS® MRI lexicon. B-CAD MRI, which won Frost & Sullivan's 2006 Medical Imaging Technology Innovation of the Year award, analyzes physical characteristics, such as a lesion's size and margin, building on traditional analysis of MRI images. B-CAD MRI then produces a detailed standardized report in compliance with the ACR BI-RADS® lexicon.

Confirma's CADstream is advancing breast MRI by enhancing efficiency, standardization, access, and compatibility of studies. The CADstream system automates analysis, reporting, and interventional planning of studies and promotes standardization with the incorporation of the ACR BI-RADS® Atlas. CADstream is designed for any workflow scenario, integrating with existing equipment and providing access to studies anywhere on the network. Automated features include adaptive image registration (2D/3D), multiplanar reformatting, subtractions, angiogenesis maps, curves, maximum intensity projections (MIPs), volume summaries, morphology characterization, portfolio for reporting, SureLoc for interventional guidance, and multimodality capability.

About The Medipattern Corporation

The Medipattern Corporation develops computer-aided diagnosis (CAD) software applications for medical imaging. These applications enhance workflow while improving interpretive and diagnostic confidence. The Company's initial clinical applications are B-CAD™ for breast ultrasound and the award-winning B-CAD MRI™. The B-CAD products use pattern recognition technology to assist radiologists in their efforts to classify and characterize lesions in images of the breast. For additional information, please visit the company's website at: www.medipattern.com.

About Confirma, Inc.

Confirma, Inc. develops and markets computer-aided-detection (CAD) systems and accessories for medical imaging. CADstream™ is the standard in CAD for magnetic resonance imaging (MRI). CADstream automates the processing of MRI studies, providing higher quality imaging studies, lower costs for radiology practices and improved communication tools for physicians and patients. In its initial application, CADstream is being used to assist in the analysis, interventional guidance and reporting of breast MRI studies. CADstream is DICOM 3.0 compliant, allowing integration with any MRI scanner and PACS. Confirma has established partnerships with companies including GE Healthcare, Hologic, iCAD and Vital Images. Confirma has partnered with more than 200 imaging centers and corporate partners worldwide since 2003, helping develop more standardized, high performance breast MRI programs that deliver premium patient care. For more information, visit www.confirma.com or call 877/811-2356.

The Medipattern Corporation develops computer-aided diagnosis (CAD) software applications for medical imaging. These applications enhance workflow while improving interpretive and diagnostic confidence. The Company's initial clinical applications are B-CAD™ for breast ultrasound and B-CAD MRI™. The B-CAD products use pattern recognition technology to assist radiologists in their efforts to classify and characterize lesions in images of the breast. For additional information, please visit the company's website at: www.medipattern.com.

B-CAD™ is a trademark of The Medipattern Corporation.

I-ReadMammo™ is a trademark of Cedara Software Corp.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential", and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at www.sedar.com). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved of the contents of this release.

Contact Information